Stay updated on EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial
Sign up to get notified when there's something new on the EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial page.

Latest updates to the EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe ClinicalTrials.gov record for the EA-2353 retinitis pigmentosa study is now displayed, including its terminated status and detailed study information.SummaryDifference41%

- Check16 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0 while the page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check23 days agoChange DetectedA banner announces an NIH website transition and says the term “Super Intelligence” is being used in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1 on a 403 Forbidden error page.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content and signaling restricted access to the study page.SummaryDifference17%

Stay in the know with updates to EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial page.